Reducing Intracranial atheroSclErosis With Repatha

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, Los Angeles
Study ID
NCT04573777
Phase
PHASE4
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Repatha — DRUG
    140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor

Study Details

The purpose of this study will be to understand the underlying mechanism by which PCSK9 inhibition reduces the rate of ischemic stroke seen in the pivotal studies that led to its FDA approval for ASCVD such as ischemic stroke. Those trials (FOURIER and ODYSSEY) enrolled almost 50,000 patients and showed that PCSK9 inhibition therapy is safe and effective. The investigators hypothesize that PCSK9 inhibition lowers the rate of stroke by reducing atherosclerotic plaque, which would be particularly beneficial for patients with intracranial atherosclerosis, who have the highest rate of recurrent stroke of any stroke mechanism.

Key Dates

Start date
Apr 23, 2021
Status verified
Feb 2023
Primary completion
Dec 16, 2021
Completion
Dec 16, 2021

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention Repatha

Primary Outcome Measure

Stenosis [ Time Frame: 1.5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCLALos AngelesCalifornia90095-

Find similar trials in Los Angeles, CA

By condition
Stroke
By specialty
NeurologyBrain disorders
By research site
UCLA· Los Angeles, CA

Related Studies